Stock ACXP ACURX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
2.03 USD -0.49% Intraday chart for Acurx Pharmaceuticals, Inc. +12.78% -47.00%
Apr. 04 Top Premarket Gainers MT
Mar. 19 H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
PR
Top Premarket Gainers
MT
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV
NE
H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating
MT
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected
MT
US Futures Trend Lower in Tuesday's Premarket as Investors Await Start of 2-Day Fed Meeting
MT
Transcript : Acurx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
PR
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
PR
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
AQ
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
PR
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
PR
Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients
CI
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024, February 1, 2024
AQ
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
PR
Acurx Pharmaceuticals' Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)
AQ
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
PR
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients
CI
Transcript : Acurx Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACXP Stock
  4. News Acurx Pharmaceuticals, Inc.